NASDAQ:JAZZ - Jazz Pharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Jazz Pharmaceuticals PLC Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $99.60 +2.64 (+2.72 %) (As of 03/31/2020 03:44 AM ET) Add Compare Today's Range$97.24Now: $99.60▼$101.5950-Day Range$87.74MA: $118.42▼$144.3852-Week Range$86.88Now: $99.60▼$154.24Volume569,384 shsAverage Volume959,216 shsMarket Capitalization$5.59 billionP/E Ratio10.95Dividend YieldN/ABeta1.32 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology. Its lead marketed products include Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in adult and pediatric patients with narcolepsy; Erwinaze to treat acute lymphoblastic leukemia; Defitelio for the treatment of adult and pediatric patients with hepatic veno-occlusive disease, a potentially life-threatening complication of hematopoietic stem cell transplantation; and Vyxeos liposome for injection, a product for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia. The company also develops Solriamfetol for the treatment of EDS in patients with narcolepsy and obstructive sleep apnea, as well as in Phase II clinical trial for EDS associated with Parkinson's disease; Vyxeos for acute myeloid leukemia; and JZP-258 to treat EDS and cataplexy with narcolepsy and potential treatment of idiopathic hypersomnia and a chronic neurological disorder. In addition, it sells psychiatry and other products. Jazz Pharmaceuticals plc has licensing and collaboration agreements with ImmunoGen, Inc.; Codiak BioSciences, Inc.; Pfenex, Inc.; and XL-protein GmbH. The company is headquartered in Dublin, Ireland.Read More Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals SectorMedical Current SymbolNASDAQ:JAZZ Previous Symbol CUSIPG5087110 CIK1232524 Webhttp://www.jazzpharma.com/ Phone011-353-1634-7800Debt Debt-to-Equity Ratio0.55 Current Ratio4.47 Quick Ratio4.26Price-To-Earnings Trailing P/E Ratio10.95 Forward P/E Ratio6.22 P/E Growth0.52 Sales & Book Value Annual Sales$2.16 billion Price / Sales2.59 Cash Flow$22.84 per share Price / Cash Flow4.36 Book Value$54.99 per share Price / Book1.81Profitability EPS (Most Recent Fiscal Year)$14.60 Net Income$523.37 million Net Margins24.21% Return on Equity28.29% Return on Assets15.39%Miscellaneous Employees1,620 Outstanding Shares56,130,000Market Cap$5.59 billion Next Earnings Date5/5/2020 (Estimated) OptionableOptionable Receive JAZZ News and Ratings via Email Sign-up to receive the latest news and ratings for JAZZ and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:JAZZ Rates by TradingView Jazz Pharmaceuticals (NASDAQ:JAZZ) Frequently Asked Questions How has Jazz Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)? Jazz Pharmaceuticals' stock was trading at $108.04 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, JAZZ shares have decreased by 7.8% and is now trading at $99.60. View which stocks have been mosted impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Jazz Pharmaceuticals? 15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Jazz Pharmaceuticals in the last year. There are currently 4 hold ratings and 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Jazz Pharmaceuticals. When is Jazz Pharmaceuticals' next earnings date? Jazz Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, May 5th 2020. View our earnings forecast for Jazz Pharmaceuticals. How were Jazz Pharmaceuticals' earnings last quarter? Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) released its earnings results on Tuesday, February, 25th. The specialty pharmaceutical company reported $4.42 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $3.61 by $0.81. The specialty pharmaceutical company had revenue of $581.70 million for the quarter, compared to analyst estimates of $545.12 million. Jazz Pharmaceuticals had a net margin of 24.21% and a return on equity of 28.29%. The company's revenue for the quarter was up 22.1% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $3.64 earnings per share. View Jazz Pharmaceuticals' earnings history. What guidance has Jazz Pharmaceuticals issued on next quarter's earnings? Jazz Pharmaceuticals issued an update on its FY20 earnings guidance on Tuesday, February, 25th. The company provided earnings per share guidance of $12.50-$13.40 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $17.05. The company issued revenue guidance of $2.32-$2.40 billion, compared to the consensus revenue estimate of $2.32 billion. What price target have analysts set for JAZZ? 15 brokers have issued 12-month price targets for Jazz Pharmaceuticals' shares. Their forecasts range from $129.00 to $205.00. On average, they expect Jazz Pharmaceuticals' share price to reach $165.60 in the next twelve months. This suggests a possible upside of 66.3% from the stock's current price. View analysts' price targets for Jazz Pharmaceuticals. What are Wall Street analysts saying about Jazz Pharmaceuticals stock? Here are some recent quotes from research analysts about Jazz Pharmaceuticals stock: 1. According to Zacks Investment Research, "Jazz’s key drug, Xyrem, continues to witness improved volume trends in 2019 on the back of awareness efforts. The label expansion of Xyrem in pediatric patients has improved the top line further. Management expects Xyrem's volume growth to continue in the second half. Sunosi's launch in July 2019 complements the sleep franchise and its successful commercialization may offset a decline in Xyrem’s sales following patent expiry in 2023. Jazz’s leukemia drug, Vyxeos, has also witnessed strong growth so far in 2019. Its launch in Europe boosted sales in 2019. However, Jazz has been facing supply crunch for its leukemia drug, Erwinaze, owing to constrained manufacturing capacity, which is likely to continue in second half. Defitelio sales also vary every quarter." (9/13/2019) 2. HC Wainwright analysts commented, "Our $147 12-month target (from $153) is based on a DCF, which reflects a strong 15% 2019-22 cash- flow CAGR, a 10% WACC discount rate, and negative 3.5% terminal growth after 2022 given conservatively assumed modest Xyrem franchise headwinds partially offset by other products’ continued growth." (8/8/2019) Has Jazz Pharmaceuticals been receiving favorable news coverage? Media headlines about JAZZ stock have trended very negative on Tuesday, according to InfoTrie Sentiment Analysis. The research firm rates the sentiment of media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Jazz Pharmaceuticals earned a media sentiment score of -3.7 on InfoTrie's scale. They also assigned news stories about the specialty pharmaceutical company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock's share price in the immediate future. View the latest news aboutJazz Pharmaceuticals. Are investors shorting Jazz Pharmaceuticals? Jazz Pharmaceuticals saw a decrease in short interest in March. As of March 13th, there was short interest totaling 3,174,500 shares, a decrease of 8.0% from the February 27th total of 3,450,000 shares. Based on an average trading volume of 987,600 shares, the days-to-cover ratio is presently 3.2 days. Approximately 5.8% of the shares of the stock are sold short. View Jazz Pharmaceuticals' Current Options Chain. Who are some of Jazz Pharmaceuticals' key competitors? Some companies that are related to Jazz Pharmaceuticals include Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Pfizer (PFE), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), AbbVie (ABBV), Allergan (AGN), Zoetis (ZTS), Mylan (MYL), Perrigo (PRGO), Horizon Therapeutics (HZNP), Nektar Therapeutics (NKTR), Pacira Biosciences (PCRX), Corcept Therapeutics (CORT) and Zogenix (ZGNX). What other stocks do shareholders of Jazz Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Jazz Pharmaceuticals investors own include Ligand Pharmaceuticals (LGND), Gilead Sciences (GILD), Alibaba Group (BABA), Netflix (NFLX), Micron Technology (MU), NVIDIA (NVDA), Skyworks Solutions (SWKS), Baidu (BIDU), Visa (V) and Tesla (TSLA). Who are Jazz Pharmaceuticals' key executives? Jazz Pharmaceuticals' management team includes the following people: Mr. Bruce C. Cozadd, Co-Founder, Chairman & CEO (Age 55)Mr. Matthew P. Young, Exec. VP & CFO (Age 50)Mr. Daniel N. Swisher Jr., Pres & COO (Age 56)Ms. Karen J. Wilson, Sr. VP of Fin. & Principal Accounting Officer (Age 56)Mr. Paul Treacy, Sr. VP of Technical Operations (Age 58) What is Jazz Pharmaceuticals' stock symbol? Jazz Pharmaceuticals trades on the NASDAQ under the ticker symbol "JAZZ." How do I buy shares of Jazz Pharmaceuticals? Shares of JAZZ can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Jazz Pharmaceuticals' stock price today? One share of JAZZ stock can currently be purchased for approximately $99.60. How big of a company is Jazz Pharmaceuticals? Jazz Pharmaceuticals has a market capitalization of $5.59 billion and generates $2.16 billion in revenue each year. The specialty pharmaceutical company earns $523.37 million in net income (profit) each year or $14.60 on an earnings per share basis. Jazz Pharmaceuticals employs 1,620 workers across the globe. View additional information about Jazz Pharmaceuticals. What is Jazz Pharmaceuticals' official website? The official website for Jazz Pharmaceuticals is http://www.jazzpharma.com/. How can I contact Jazz Pharmaceuticals? Jazz Pharmaceuticals' mailing address is FIFTH FLOOR WATERLOO EXCHANGE WATERLOO ROAD, DUBLIN L2, D04. The specialty pharmaceutical company can be reached via phone at 011-353-1634-7800 or via email at [email protected] MarketBeat Community Rating for Jazz Pharmaceuticals (NASDAQ JAZZ)Community Ranking: 3.4 out of 5 ( )Outperform Votes: 959 (Vote Outperform)Underperform Votes: 445 (Vote Underperform)Total Votes: 1,404MarketBeat's community ratings are surveys of what our community members think about Jazz Pharmaceuticals and other stocks. Vote "Outperform" if you believe JAZZ will outperform the S&P 500 over the long term. Vote "Underperform" if you believe JAZZ will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 3/31/2020 by MarketBeat.com StaffFeatured Article: What are retained earnings?
